FIBK enters the back half of May with a notable split in its positioning story — shorts are retreating from a mid-month spike even as a fresh analyst downgrade lands on the stock.
The most pressing news this week is from DA Davidson. Analyst Jeff Rulis downgraded FIBK to Neutral from Buy on May 27, cutting his target to $39 from $41. That move is especially pointed because Rulis had only lifted his target to $41 on May 1 — less than a month ago — after the Q1 print. The reversal follows a broader wave of Street caution. Keefe, Bruyette & Woods had already cut to Market Perform from Outperform on May 1, moving its target down to $37. UBS, which downgraded to Sell back in early April, nudged its target up to $33. The net result: five analysts, zero Buys, a consensus Hold, and a mean target of $37 — barely above the current price of $36.13. The bulls have gone quiet.
Short positioning tells a story that has been rapidly shifting. SI % of Free Float peaked at 16.4% on May 11 — an unusually elevated reading for a mid-sized regional bank — before falling sharply as the stock recovered. It has come back to 13.3% as of May 26, still elevated compared to the 10% range where it traded through April. The one-month change is still a hefty +32%, meaning the short base built aggressively in late April and early May even as it has begun to unwind. Borrowing costs have been easing alongside: cost to borrow is running at 0.47% APR, down about 7% on the week and 13% over the past month, suggesting borrow demand is fading. Availability remains generous at 424% of short interest, well clear of any squeeze territory.
Options positioning skews defensive but not extreme. The put/call ratio of 2.98 is above its 20-day average of 2.27, but the z-score of 0.56 places it less than one standard deviation above the mean — notably elevated versus the April period when PCR ran below 0.4, but not a flashing signal. The jump in PCR that began around May 6-8 coincides almost exactly with the SI surge, suggesting both options traders and short sellers became more cautious in the same window.
The bull case rests on valuation and income. At a P/E of 13.1 and a price-to-book just above par at 1.02, the stock is not expensive for a franchise with a reasonable capital deployment record and an active buyback. The bear case focuses on loan portfolio risks: growth has been soft, credit quality in FIBK's concentrated Mountain West footprint is the key watch item, and the forward EPS growth picture — which ranks in only the 6th percentile for 12-month year-on-year improvement — offers little upside support. The ORTEX short score of 64.8 ranks in the 1st percentile of the stock's own history, reflecting how unusual the current level of short interest is relative to prior readings.
Insider activity adds a modest negative tint. Former Director Jonathan R. Scott sold 53,504 shares on April 30 for just under $1.9 million, following a smaller $100K sale in March. The CEO and CFO also made smaller, routine sales in March. Net insider activity over 90 days shows a net positive of roughly 125,600 shares, but that figure is mostly explained by equity awards rather than open-market purchases. No insider has been a net buyer.
Peers have broadly tracked FIBK's weekly rebound. FNB, WAL, COLB, and ZION all gained 2–4% on the week versus FIBK's 5.2% move, suggesting the outperformance is partly FIBK-specific rather than pure sector tailwind. The next confirmed earnings event is July 24 — the print will be the first real test of whether the Street's freshly cautious positioning was warranted.
See the live data behind this article on ORTEX.
Open FIBK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
